We're thrilled to announce that Omic has reached profitability—a significant milestone for our bootstrapped company—and is accelerating investment in our platform and pipeline.

## Sustainable Growth

Since launching our Digital Patient platform in 2020, we've seen strong demand from pharmaceutical partners:

- **100+ Digital Patient models** built for partner programs
- **85% accuracy** in predicting drug response in retrospective validation
- **3 partnership agreements** with pharmaceutical companies
- **Team growth** from 6 to 10 employees

Revenue from these partnerships now exceeds our operating costs, allowing us to reinvest in growth while maintaining our independence.

## Internal Pipeline Programs

We're using our profits to launch internal drug discovery programs in areas where our AI has identified compelling opportunities:

- **Oncology**: Novel targets for treatment-resistant cancers
- **Metabolic disease**: New approaches to diabetes and obesity
- **Autoimmune**: Precision targets for inflammatory conditions

These programs will be fully internal, using our AI platform to drive every stage from target discovery through lead optimization.

## Platform Expansion

We're also significantly expanding our platform capabilities:

- **Generative chemistry**: AI systems that design novel drug molecules
- **Virtual clinical trials**: Larger-scale simulation of clinical outcomes
- **Real-world evidence integration**: Connecting Digital Patients to clinical outcomes data

## Why Bootstrapped Works

Reaching profitability as a bootstrapped company validates our approach. We've proven that you can build serious drug discovery technology without venture funding—and that doing so creates better alignment with the long-term nature of pharmaceutical development.

Our partners appreciate working with a company that isn't under pressure to show hockey-stick growth or position for an exit. We're here to discover drugs, not flip a company.

## Team Growth

We're hiring across all functions:

- **Computational biology** and **machine learning** to advance our AI
- **Medicinal chemistry** to support internal programs
- **Clinical development** to plan for eventual human studies
- **Business development** to expand partnerships

We expect to grow significantly over the next 18 months, funded by our growing partnership business.